Related Experiment Video

Updated: Mar 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations

Leanne G Ahronian1, Ryan B Corcoran1

  • 1Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Molecular & Cellular Oncology
|June 17, 2016
PubMed

Insights

RAF inhibitor combinations show promise for BRAF-mutant colorectal cancer (CRC) by suppressing MAPK signaling. However, acquired resistance emerges through MAPK pathway reactivation, highlighting it as a key therapeutic target in CRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • RAF inhibitor monotherapy lacks efficacy in BRAF-mutant colorectal cancer (CRC).
  • Combination therapies involving RAF inhibitors demonstrate improved efficacy in BRAF-mutant CRC.
  • MAPK signaling pathway suppression is a likely mechanism for enhanced efficacy.

Purpose of the Study:

  • To investigate the efficacy of RAF inhibitor combinations in BRAF-mutant CRC.
  • To identify mechanisms of acquired resistance to RAF inhibitor combinations.
  • To underscore the importance of the MAPK pathway as a therapeutic target.

Main Methods:

  • Utilized RAF inhibitor combinations in preclinical models of BRAF-mutant CRC.
  • Analyzed signaling pathway activity, focusing on MAPK.
  • Investigated mechanisms leading to acquired resistance.

Main Results:

  • RAF inhibitor combinations show superior suppression of MAPK signaling compared to monotherapy.
  • The primary mechanisms of acquired resistance involve reactivation of the MAPK pathway.
  • MAPK pathway reactivation is a consistent finding across different resistance models.

Conclusions:

  • RAF inhibitor combinations represent a viable strategy for BRAF-mutant CRC treatment.
  • Targeting MAPK reactivation is crucial for overcoming acquired resistance.
  • The MAPK pathway remains a critical target for therapeutic intervention in BRAF-mutant CRC.
Keywords:
BRAFBRAF inhibitorClinical trialsERK inhibitorMAPKcolorectal cancerresistance

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K